TOday’s Movers: Impax Laboratories (NASDAQ:IPXL) Stock Rating Reaffirmed by Analysts at Deutsche Bank; $21 Target Price Indicates 15.58 % Potential

July 17, 2017 - By Dolores Ford

 TOday’s Movers: Impax Laboratories (NASDAQ:IPXL) Stock Rating Reaffirmed by Analysts at Deutsche Bank; $21 Target Price Indicates 15.58 % Potential

Investors sentiment decreased to 1.18 in 2016 Q4. Its down 0.25, from 1.43 in 2016Q3. It fall, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. 36 funds opened positions while 61 raised stakes. 57.71 million shares or 5.44% less from 61.03 million shares in 2016Q3 were reported.

Tocqueville Asset Management Lp holds 19,152 shares. Aqr Cap holds 0% in Impax Laboratories Inc (NASDAQ:IPXL) or 25,429 shares. Ubs Asset Management Americas owns 0% invested in Impax Laboratories Inc (NASDAQ:IPXL) for 15,416 shares. Ny State Common Retirement Fund holds 0% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL) for 79,500 shares. Jacobs Levy Equity Inc invested in 0.05% or 185,015 shares. Putnam Invests Lc holds 39,336 shares or 0% of its portfolio. Reilly Advsrs Ltd, California-based fund reported 500 shares. Guggenheim Capital Ltd Liability invested in 145,928 shares or 0.01% of the stock. Moreover, Wells Fargo And Company Mn has 0% invested in Impax Laboratories Inc (NASDAQ:IPXL). accumulated 53,775 shares. Blackrock Fund Advsrs stated it has 0.01% in Impax Laboratories Inc (NASDAQ:IPXL). State Of Alaska Department Of Revenue reported 7,990 shares stake. Savings Bank Of Montreal Can invested 0% in Impax Laboratories Inc (NASDAQ:IPXL). Ameriprise Incorporated owns 2.39 million shares or 0.02% of their US portfolio. Wellington Mngmt Grp Ltd Liability Partnership stated it has 0% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL).

Since May 12, 2017, it had 0 insider purchases, and 3 insider sales for $43,046 activity.

Impax Laboratories (NASDAQ:IPXL) Rating Reaffirmed

Stock research analysts at Deutsche Bank now has a $21 TP on Impax Laboratories (NASDAQ:IPXL). Deutsche Bank and their recent TP means a potential upside of 15.58 % from the company’s last stock price. The rating has been disclosed to clients in analysts report on 17 July.

Investors sentiment decreased to 1.18 in 2016 Q4. Its down 0.25, from 1.43 in 2016Q3. It fall, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. 36 funds opened positions while 61 raised stakes. 57.71 million shares or 5.44% less from 61.03 million shares in 2016Q3 were reported.

Tocqueville Asset Management Lp holds 19,152 shares. Aqr Cap holds 0% in Impax Laboratories Inc (NASDAQ:IPXL) or 25,429 shares. Ubs Asset Management Americas owns 0% invested in Impax Laboratories Inc (NASDAQ:IPXL) for 15,416 shares. Ny State Common Retirement Fund holds 0% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL) for 79,500 shares. Jacobs Levy Equity Inc invested in 0.05% or 185,015 shares. Putnam Invests Lc holds 39,336 shares or 0% of its portfolio. Reilly Advsrs Ltd, California-based fund reported 500 shares. Guggenheim Capital Ltd Liability invested in 145,928 shares or 0.01% of the stock. Moreover, Wells Fargo And Company Mn has 0% invested in Impax Laboratories Inc (NASDAQ:IPXL). accumulated 53,775 shares. Blackrock Fund Advsrs stated it has 0.01% in Impax Laboratories Inc (NASDAQ:IPXL). State Of Alaska Department Of Revenue reported 7,990 shares stake. Savings Bank Of Montreal Can invested 0% in Impax Laboratories Inc (NASDAQ:IPXL). Ameriprise Incorporated owns 2.39 million shares or 0.02% of their US portfolio. Wellington Mngmt Grp Ltd Liability Partnership stated it has 0% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL).

Since May 12, 2017, it had 0 insider purchases, and 3 insider sales for $43,046 activity.

Impax Laboratories Inc (NASDAQ:IPXL) Ratings Coverage

Among 15 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Impax Laboratories Inc. has $60 highest and $1500 lowest target. $29.46’s average target is 62.14% above currents $18.17 stock price. Impax Laboratories Inc. had 24 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Monday, June 12. The stock of Impax Laboratories Inc (NASDAQ:IPXL) has “Sell” rating given on Monday, June 6 by Goldman Sachs. On Monday, November 14 the stock rating was downgraded by WallachBeth Capital to “Hold”. The firm earned “Buy” rating on Tuesday, October 6 by BTIG Research. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, February 23. The rating was downgraded by Bank of America on Monday, November 7 to “Underperform”. Goldman Sachs upgraded Impax Laboratories Inc (NASDAQ:IPXL) on Tuesday, September 27 to “Neutral” rating. The company was initiated on Wednesday, December 28 by Janney Capital. The firm has “Hold” rating by RBC Capital Markets given on Friday, July 14. Northland Capital upgraded the shares of IPXL in report on Monday, August 15 to “Outperform” rating.

About 2.57M shares traded or 79.72% up from the average. Impax Laboratories Inc (NASDAQ:IPXL) has declined 49.01% since July 17, 2016 and is downtrending. It has underperformed by 65.71% the S&P500.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The company has market cap of $1.33 billion. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , in addition to the development and marketing of branded products. It currently has negative earnings. The Company’s divisions include Impax Generics and Impax Specialty Pharma.

More important recent Impax Laboratories Inc (NASDAQ:IPXL) news were published by: Prnewswire.com which released: “Impax Announces FDA Approval and Launch of Additional Strengths of Generic …” on July 05, 2017, also Thestreet.com published article titled: “Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta”, Streetinsider.com published: “Impax Laboratories (IPXL) Receives FDA Approval for AB Rated Generic Concerta …” on July 17, 2017. More interesting news about Impax Laboratories Inc (NASDAQ:IPXL) was released by: Prnewswire.com and their article: “Impax to Report Second Quarter 2017 Results on August 9, 2017” with publication date: June 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.